Primary and secondary outcomes
| . | n (%) . | 95% CI . |
|---|---|---|
| Safety, bleeding events | ||
| Major | 0 (0) | <0.4 |
| Clinically relevant nonmajor | 3 (0.5) | 0.1-1.4 |
| Minor | 60 (9.6) | 7.4-12.2 |
| Major complications* | 0 (0) | 0.0-0.6 |
| Feasibility | ||
| Patients included in the study | 624 (37.7) | 35.4-40.1 |
| . | n (%) . | 95% CI . |
|---|---|---|
| Safety, bleeding events | ||
| Major | 0 (0) | <0.4 |
| Clinically relevant nonmajor | 3 (0.5) | 0.1-1.4 |
| Minor | 60 (9.6) | 7.4-12.2 |
| Major complications* | 0 (0) | 0.0-0.6 |
| Feasibility | ||
| Patients included in the study | 624 (37.7) | 35.4-40.1 |
Worsening of symptoms, development of symptoms, or signs of PE between inclusion and diagnosis of VTE.